BioPharma « Terug naar discussie overzicht

GlobeImmune

4 Posts

Omlaag ↓

[verwijderd] 3 april 2015 14:46

Van de week kwam ik via een Amerikaans forum dit biotech bedrijfje tegen.

We are a biopharmaceutical company established in 1995 focused on developing products for the treatment of cancer and infectious diseases based on our proprietary Tarmogen® platform. Tarmogens activate a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines, which predominately stimulate antibody production. We have four Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications.

Strategic alliance with Gilead for chronic hepatitis B virus (HBV) infection. In October 2011, Gilead Sciences, Inc., exclusively licensed product candidates to treat chronic hepatitis B virus (HBV) infection. Our world-wide collaboration with Gilead is focused on developing a lead product candidate, GS-4774, to target patients chronically infected with HBV who are also on, or are candidates for, oral antiviral suppressive therapy. Gilead is responsible for all future clinical, regulatory and commercial activities.

Strategic collaboration and option agreement with Celgene for cancer. In May 2009, we entered into a worldwide strategic collaboration and option agreement with Celgene focused on the discovery, development and commercialization of certain product candidates for the treatment of cancer. For product candidates subject to option by Celgene, we are responsible for initial development under the agreement, and Celgene has the option to license each of them at specific points in the development plan. Upon the achievement of certain development, regulatory and commercial milestones, we would be eligible to receive milestone payments and tiered royalties based on net sales of each licensed product. Under this agreement, in July 2013 Celgene exercised its option for a worldwide, exclusive license to the GI-6300 program, including GI-6301, which is a Tarmogen program targeting the brachyury protein.

National Institutes of Health (NIH) – Cooperative Research and Development Agreement. We are party to a Cooperative Research and Development Agreement (CRADA) originally signed in May 2008 and renewed in October 2013, with the NIH. The CRADA is for the preclinical and clinical development of our proprietary yeast-based Tarmogens expressing tumor-associated antigens as potential vaccines for the prevention and/or therapy of a range of human cancers.

www.globeimmune.com/

Celgene is hun grootste aandeelhouder en hebben hun stukken op $10,-- aangeschaft. Directie en institutionele aandeelhouders hebben ongeveer 50% van de aandelen in handen. Totaal staan er maar 5,6 miljoen aandelen uit. Ze hebben een goedgevulde pijplijn en komende maanden komen de resultaten van hun fase 2 Hepatitis B naar buiten. Dit doen ze in samenwerking met Gilead. Niet de kleinste jongens dus waar ze mee samen werken. Ik zou zeggen check hun site het is de moeite waard.

[verwijderd] 3 april 2015 14:56

Ben benieuwd hoe andere bio beleggers hier tegenaan kijken.

[verwijderd] 3 april 2015 15:10

Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

This study has been completed.

clinicaltrials.gov/show/NCT01943799

=============================

— Christine M. Kukka, Project Manager, HBV Advocate

One of the most unique hepatitis B clinical trials to come along in years is currently recruiting hepatitis B patients to assess the effectiveness of a therapeutic vaccine combined with antiviral treatment.

Gilead Sciences Inc. is leading the Phase 2 clinical trial, and is recruiting 175 patients (age 18 and older, without cirrhosis) who are currently receiving any type of U.S. Food and Drug Administration-approved antiviral (such as tenofovir (Viread), entecavir (Baraclude) and others.)

hbvadvocat.blogspot.nl/search/label/T...

[verwijderd] 28 mei 2015 09:49

Kopen op de megadip nu? Ze zijn flink afgestraft op het falen van een medicijn, maar hebben nog veel meer in de pijplijn zitten.

4 Posts

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 928,19 +5,07 +0,55% 18:05


Germany40^	18.159,10	+0,50%
BEL 20	3.865,43	+0,85%
EURO50	4.924,03	+0,39%
US30^	38.767,60	-0,04%
Nasd100^	19.905,10	-0,03%
US500^	5.480,82	+0,11%
Japan225^	38.561,80	+0,32%
Gold spot	2.329,31	+0,44%
EUR/USD	1,0742	+0,09%
WTI	80,21	+0,51%